CA3011880A1 - Substituted cyanoindoline derivatives as nik inhibitors - Google Patents

Substituted cyanoindoline derivatives as nik inhibitors Download PDF

Info

Publication number
CA3011880A1
CA3011880A1 CA3011880A CA3011880A CA3011880A1 CA 3011880 A1 CA3011880 A1 CA 3011880A1 CA 3011880 A CA3011880 A CA 3011880A CA 3011880 A CA3011880 A CA 3011880A CA 3011880 A1 CA3011880 A1 CA 3011880A1
Authority
CA
Canada
Prior art keywords
4alkyl
substituted
optionally
group
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3011880A
Other languages
English (en)
French (fr)
Inventor
Ian Stansfield
Olivier Alexis Georges Querolle
Virginie Sophie Poncelet
Gerhard Max GROSS
Edgar Jacoby
Lieven Meerpoel
Janusz Jozef Kulagowski
Calum Macleod
Samuel Edward MANN
Simon Richard Green
George Hynd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3011880A1 publication Critical patent/CA3011880A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3011880A 2016-01-22 2017-01-20 Substituted cyanoindoline derivatives as nik inhibitors Pending CA3011880A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16152416 2016-01-22
EP16152416.0 2016-01-22
EP16159651.5 2016-03-10
EP16159651 2016-03-10
PCT/EP2017/051150 WO2017125530A1 (en) 2016-01-22 2017-01-20 New substituted cyanoindoline derivatives as nik inhibitors

Publications (1)

Publication Number Publication Date
CA3011880A1 true CA3011880A1 (en) 2017-07-27

Family

ID=57868252

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3011880A Pending CA3011880A1 (en) 2016-01-22 2017-01-20 Substituted cyanoindoline derivatives as nik inhibitors

Country Status (20)

Country Link
US (1) US11180487B2 (enExample)
EP (1) EP3405196B1 (enExample)
JP (1) JP6910359B2 (enExample)
KR (1) KR102784966B1 (enExample)
CN (1) CN108697710B (enExample)
AU (1) AU2017209935B2 (enExample)
BR (1) BR112018014675B1 (enExample)
CA (1) CA3011880A1 (enExample)
DK (1) DK3405196T3 (enExample)
ES (1) ES2775449T3 (enExample)
HR (1) HRP20200133T1 (enExample)
HU (1) HUE047684T2 (enExample)
IL (1) IL260500B (enExample)
LT (1) LT3405196T (enExample)
MX (1) MX2018008974A (enExample)
PH (1) PH12018501567A1 (enExample)
SI (1) SI3405196T1 (enExample)
TW (1) TWI739783B (enExample)
WO (1) WO2017125530A1 (enExample)
ZA (1) ZA201804688B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697710B (zh) 2016-01-22 2022-02-18 杨森制药有限公司 作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物
US11001569B2 (en) 2016-01-22 2021-05-11 Janssen Pharmaceutica Nv 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
US11136311B2 (en) 2016-06-30 2021-10-05 Janssen Pharmaceutica Nv Heteroaromatic derivatives as NIK inhibitors
AU2017289317B2 (en) 2016-06-30 2021-04-01 Janssen Pharmaceutica Nv Cyanoindoline derivatives as NIK inhibitors
WO2018019204A1 (zh) 2016-07-26 2018-02-01 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
AU2018339722B2 (en) * 2017-09-30 2022-06-30 Haihe Biopharma Co., Ltd Compound having ERK kinase inhibitory activity and use thereof
TW202045008A (zh) 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途
CA3135929A1 (en) * 2019-04-02 2020-10-08 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators
PE20220768A1 (es) 2019-05-31 2022-05-16 Janssen Pharmaceutica Nv Inhibidores de molecula pequena de quinasa inductora de nf-kb
HUE068185T2 (hu) 2020-05-08 2024-12-28 Halia Therapeutics Inc NEK7-kináz inhibitorok
EP4393508A4 (en) * 2021-08-23 2024-12-04 Osaka University COMPOSITION FOR SUPPRESSING TRANSDIFFERENTIATION OF MATURE HEPATOCYTES
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
CA2441733A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1397142A4 (en) 2001-06-19 2004-11-03 Bristol Myers Squibb Co PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP2315751A1 (en) 2008-06-26 2011-05-04 Amgen Inc. Alkynyl alcohols as kinase inhibitors
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN102753177A (zh) 2009-08-17 2012-10-24 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
US8791136B2 (en) 2010-07-29 2014-07-29 Rigel Pharmaceuticals, Inc. Substituted pyridine, pyridazine, pyrazine and pyrimidine compounds and methods for using the same
EP2696683A4 (en) * 2011-04-12 2014-08-13 Alzheimer S Inst Of America Inc COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF IKK-MEDIATED KINASE EPSILON AND TANK BINDING KINASE-1 HEMMER
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
MX370588B (es) 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
EP3489232A3 (en) 2014-04-04 2019-07-31 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2946164A1 (en) 2014-05-22 2015-11-26 The University Of Sydney Omega-3 analogues
WO2016022645A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
WO2016049211A1 (en) 2014-09-26 2016-03-31 Gilead Sciences, Inc. Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
CN106928216A (zh) 2015-12-31 2017-07-07 中国科学院上海药物研究所 具有erk激酶抑制活性的化合物、其制备方法和用途
US11001569B2 (en) 2016-01-22 2021-05-11 Janssen Pharmaceutica Nv 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
CN108697710B (zh) 2016-01-22 2022-02-18 杨森制药有限公司 作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物
FI3429591T3 (fi) 2016-03-16 2023-06-15 Kura Oncology Inc Substituoituja tieno[2,3-d]pyrimidiinijohdannaisia meniini-mll:n estäjinä ja käyttömenetelmiä
US11136311B2 (en) 2016-06-30 2021-10-05 Janssen Pharmaceutica Nv Heteroaromatic derivatives as NIK inhibitors
AU2017289317B2 (en) 2016-06-30 2021-04-01 Janssen Pharmaceutica Nv Cyanoindoline derivatives as NIK inhibitors

Also Published As

Publication number Publication date
US11180487B2 (en) 2021-11-23
IL260500B (en) 2021-01-31
CN108697710B (zh) 2022-02-18
MX2018008974A (es) 2018-11-09
PH12018501567A1 (en) 2019-01-28
HUE047684T2 (hu) 2020-05-28
EP3405196A1 (en) 2018-11-28
CN108697710A (zh) 2018-10-23
KR102784966B1 (ko) 2025-03-20
EP3405196B1 (en) 2019-12-04
DK3405196T3 (en) 2020-03-09
JP6910359B2 (ja) 2021-07-28
TW201728577A (zh) 2017-08-16
AU2017209935A1 (en) 2018-08-09
BR112018014675B1 (pt) 2023-12-19
KR20180100441A (ko) 2018-09-10
SI3405196T1 (sl) 2020-03-31
BR112018014675A2 (pt) 2018-12-11
WO2017125530A1 (en) 2017-07-27
ES2775449T3 (es) 2020-07-27
TWI739783B (zh) 2021-09-21
ZA201804688B (en) 2022-03-30
AU2017209935B2 (en) 2021-04-01
HRP20200133T1 (hr) 2020-05-15
JP2019504067A (ja) 2019-02-14
LT3405196T (lt) 2020-02-25
US20210087182A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
CA3011880A1 (en) Substituted cyanoindoline derivatives as nik inhibitors
KR102517352B1 (ko) Nik 억제제로서의 헤테로방향족 유도체
AU2017286380B2 (en) Azabenzimidazole derivatives as PI3K beta inhibitors
AU2014327235B2 (en) New 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors
BR112020022006A2 (pt) piridazinonas como inibidores de parp7
CA3012031C (en) 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
KR20150028999A (ko) 5-아자인다졸 화합물 및 이의 사용 방법
AU2017289317B2 (en) Cyanoindoline derivatives as NIK inhibitors
WO2016062789A1 (en) New thienopyrimidine derivatives as nik inhibitors
CA3066166A1 (en) New substituted azaindoline derivatives as nik inhibitors
CA3150516A1 (en) Dna-pk inhibiting compounds
TW202417435A (zh) 用於治療之parp14之靶向蛋白質降解
CA3027418C (en) Cyanoindoline derivatives as nik inhibitors
RU2780577C2 (ru) Новые замещенные производные азаиндолина в качестве ингибиторов nik
HK1261385B (en) New substituted cyanoindoline derivatives as nik inhibitors
HK1261385A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
EA037358B1 (ru) Новые замещённые производные цианиндолина в качестве nik-ингибиторов

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220117

EEER Examination request

Effective date: 20220117

EEER Examination request

Effective date: 20220117

EEER Examination request

Effective date: 20220117

EEER Examination request

Effective date: 20220117

EEER Examination request

Effective date: 20220117

EEER Examination request

Effective date: 20220117

EEER Examination request

Effective date: 20220117

EEER Examination request

Effective date: 20220117